Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major

Pediatr Allergy Immunol. 2017 Mar;28(2):199-201. doi: 10.1111/pai.12677. Epub 2016 Dec 8.

Authors

Grace Isobel Davies¹, Domenica Davies², Sarah Charles², Sara Laura Barnes^{3

4}, Donald Bowden^{4

5}

Affiliations

¹ Alfred Health, Melbourne, Vic., Australia.
² Department of Pharmacy, Monash Health, Clayton, Vic., Australia.
³ Departments of Allergy and General Medicine, Monash Health, Clayton, Vic., Australia.
⁴ Monash University, Clayton, Vic., Australia.
⁵ Thalassaemia Services, Monash Health, Clayton, Vic., Australia.

PMID: 27797415
DOI: 10.1111/pai.12677

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Benzoates / adverse effects
Benzoates / immunology*
Benzoates / therapeutic use
Child, Preschool
Deferasirox
Desensitization, Immunologic / methods*
Female
Humans
Iron Chelating Agents / adverse effects
Iron Chelating Agents / therapeutic use*
Triazoles / adverse effects
Triazoles / immunology*
Triazoles / therapeutic use
beta-Thalassemia / drug therapy*
beta-Thalassemia / immunology

Substances

Benzoates
Iron Chelating Agents
Triazoles
Deferasirox